Rapid Nutrition AI Stock Analysis
Want to see FR:ALRPD full AI Analyst Report?
Rapid Nutrition (ALRPD) AI Stock Analysis
Rapid Nutrition
(Paris:ALRPD)
The score is driven primarily by severely weak profitability and cash flow, despite lower debt and some revenue recovery. Bearish technical positioning and an unfavorable loss-based valuation further constrain the outlook.
Rapid Nutrition (ALRPD) vs. iShares MSCI France ETF (EWQ)
- Market Cap
- EUR 10.53M
- Dividend Yield
- ―
- Average Volume (3M)
- 10.82K
- Price to Earnings (P/E)
- -0.7
- Beta (1Y)
- 1.21
- Revenue Growth
- -41.21%
- EPS Growth
- 73.08%
- Country
- France
- Employees
- 3
- Sector
- General
- Sector Strength
- 55
- Industry
- Packaged Foods
Rapid Nutrition Business Overview & Revenue Model
Company Description
Rapid Nutrition PLC is a natural healthcare enterprise that researches, develops, and manufactures a diverse portfolio of science-backed health and wellness products. Its market presence extends across the United Kingdom, Australia, Asia, the United...
Rapid Nutrition Financial Statement Overview
Summary
Financial performance is severely weak: persistent losses, negative operating and free cash flow, and continued cash-burn risk outweigh the benefits of revenue recovery and substantially reduced debt.
Income Statement
24NegativeBalance Sheet
42NeutralCash Flow
19Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 491.32K | 194.33K | 917.04K | 1.66M | 2.96M | 2.79M |
| Gross Profit | 122.53K | 52.93K | 482.09K | 817.59K | 2.08M | 2.04M |
| EBITDA | -5.43M | -2.61M | -1.52M | -1.94M | -8.64M | 594.14K |
| Net Income | -5.44M | -3.10M | -2.90M | -2.13M | -9.97M | 238.07K |
Balance Sheet | ||||||
| Total Assets | 6.10M | 9.07M | 955.55K | 918.27K | 588.30K | 2.62M |
| Cash, Cash Equivalents and Short-Term Investments | 2.24M | 8.55M | 95.81K | 488.10K | 236.12K | 77.51K |
| Total Debt | 72.41K | 77.87K | 88.08K | 194.87K | 356.03K | 2.12M |
| Total Liabilities | 502.65K | 549.66K | 574.14K | 877.66K | 480.36K | 3.53M |
| Stockholders Equity | 5.59M | 8.52M | 381.41K | 40.61K | 107.94K | -909.79K |
Cash Flow | ||||||
| Free Cash Flow | -5.43M | -3.12M | -3.00M | -1.55M | -2.36M | -146.36K |
| Operating Cash Flow | -5.43M | -3.12M | -3.00M | -1.55M | -2.36M | -146.36K |
| Investing Cash Flow | -2.95M | -1,545 | 0 | 0 | 0 | 11.16K |
| Financing Cash Flow | 13.43M | 11.59M | 2.61M | 1.80M | 1.46M | -117.24K |
Rapid Nutrition Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALRPD, the sentiment is Negative. The current price of 1.61 is below the 20-day moving average (MA) of 1.91, below the 50-day MA of 2.32, and below the 200-day MA of 7.10, indicating a bearish trend. The MACD of -0.21 indicates Negative momentum. The RSI at 33.92 is Neutral, neither overbought nor oversold. The STOCH value of 5.97 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALRPD.
Rapid Nutrition Peers Comparison
Overall Rating
FR:BLC68Neutral
FR:BOI65Neutral
FR:ALFLE50Neutral
FR:SAVE47.5Neutral
FR:BON44Neutral- FR:ALRPD39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| FR:BLC | 68Neutral | EUR 146.11M | 2.51 | 49.70% | ― | -1.79% | 10979.07% |
| FR:BOI | 65Neutral | EUR 333.73M | 12.88 | 6.82% | 7.03% | -1.80% | 35.22% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| FR:ALFLE | 50Neutral | EUR 98.62M | 10.21 | 7.40% | 14.26% | 4.46% | 133.27% |
| FR:SAVE | 48Neutral | EUR 787.24M | 9.88 | 4.13% | 2.46% | -1.53% | -12.97% |
| FR:BON | 44Neutral | EUR 284.26M | 19.21 | -3.09% | 2.77% | -0.80% | ― |
| FR:ALRPD | 39Underperform | EUR 10.53M | -0.73 | -77.10% | ― | -41.21% | 73.08% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FR:ALRPD | Rapid Nutrition | 1.61 | -2.74 | -63.08% | |
| FR:BLC | Bastide le Confort Medical | 19.88 | -6.22 | -23.83% | |
| FR:BOI | Boiron SA | 19.20 | -6.48 | -25.24% | |
| FR:BON | Bonduelle SA | 9.03 | 0.27 | 3.13% | |
| FR:ALFLE | Fleury Michon | 23.70 | -0.04 | -0.15% | |
| FR:SAVE | Savencia SA | 56.80 | -1.48 | -2.53% |
Rapid Nutrition Corporate Events
Rapid Nutrition Posts Record Q3 as Accelerated Growth Strategy Takes Hold
Rapid Nutrition PLC reported a record trading quarter for the three months to 30 September 2026, generating unaudited average Group revenue of about $1 million per month. This represents an increase of more than 1,000% over its FY2025 average monthly...
Rapid Nutrition posts surging H1 revenue and expands via HealthShop+ acquisition
Rapid Nutrition has reported unaudited interim results for the six months to 30 June 2026, showing a 227.5% increase in revenue and a 122.3% rise in gross profit versus the prior year period. The performance was driven largely by its established bran...
Rapid Nutrition triples H1 revenue and expands with HealthShop+ acquisition
Rapid Nutrition reported a 227.5% year-on-year increase in first-half revenue and a 122.3% rise in gross margin, driven primarily by its historic brands as it executes a strategic refocus begun in 2025. The company also continued to invest heavily in...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 31, 2026